EPIVIR-HBV
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIVIR-HBV is an oral small-molecule nucleoside reverse transcriptase inhibitor approved in 1998 for chronic hepatitis B infection. The drug works by inhibiting viral reverse transcriptase, reducing HBV replication and viral load in infected patients. It is administered as an oral tablet.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation and focus on transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EPIVIR-HBV offers stable but declining opportunities as the product approaches loss of exclusivity. Career growth on this product is limited; professionals should expect focus on defensive strategies, cost management, and transition planning rather than growth initiatives.
Brand ManagerRegional Sales Manager
Worked on EPIVIR-HBV at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.